This protocol describes the differentiation of naïve CD4+ T cells into pathogenic Th17 cells in vitro. Specifically, when combined with a multi-parameter flow cytometry-based approach, 90% purity of pathogenic Th17 cells can be obtained from naïve CD4+ T cells using this differentiation method.
In vitro T cell differentiation techniques are essential for both functional and mechanistic investigations of CD4+ T cells. Pathogenic Th17 cells have been linked to a wide range of diseases in recent times, including multiple sclerosis (MS), rheumatoid arthritis, acute respiratory distress syndrome (ARDS), sepsis, and other autoimmune disorders. However, the currently known in vitro differentiation protocols have difficulty achieving high purity of pathogenic Th17 cells, with the induction efficiency often below 50%, which is a key challenge in in vitro experiments. In this protocol, we propose an enhanced in vitro culture and differentiation protocol for pathogenic Th17 cells, which is used to directly differentiate naive CD4+ T cells isolated from mouse spleens into pathogenic Th17 cells. This protocol provides detailed instructions on splenocyte isolation, purification of naive CD4+ T cells, and differentiation of pathogenic Th17 cells. Through this protocol, we can achieve a differentiation purity of approximately 90% for pathogenic Th17 cells, which meets the basic needs of many cellular experiments.
After leaving the thymus, naive CD4+ T lymphocytes pass through secondary lymphoid organs. Antigen-presenting cells that transmit homologous antigens to naïve CD4+ T cells activate them, starting a series of differentiation programs that eventually result in the production of highly specialized T helper (Th) cell lineages1. Interleukin 17 (IL-17) production characterizes Th17 cells, a subpopulation of pro-inflammatory Th cells2. Th17 cells play a role in the host's defense against extracellular pathogens and in the pathogenesis of many autoimmune diseases, such as autoimmune uveitis and multiple sclerosis. Signals from T-cell receptors and cytokines IL-6 and transforming growth factor-β (TGF-β) induce the differentiation of naive T cells into Th17 cells through the phosphorylation of signal transducer and activator of transcription (STAT)33. STAT3 is further amplified in a positive feedback loop through signaling mediated by IL-23 and IL-214,5. Phosphorylation of STAT3 can induce the expression of the transcription factors RORγt and RORα, which act as master switches regulating the cytokine profile of IL-17A, IL-17F, IL-21, and IL-22 in Th17 cells6. However, it has been reported that IL-6- and TGF-β-induced Th17 cells are insufficient to trigger autoimmune diseases, which require co-stimulation by IL-23 or separate co-stimulation of IL-6, IL-1β, and IL-23 in the absence of TGF-β7,8.
Th17 subsets that cannot effectively induce experimental autoimmune encephalomyelitis (EAE) are sometimes referred to as non-pathogenic Th17 while Th17 subsets that can induce EAE are known as pathogenic Th179. Current studies have shown that although pathogenic Th17 and non-pathogenic Th17 co-express the core transcription factor RORγt, there are great differences in the ability to produce IL-17A and pro-inflammatory and anti-inflammatory properties10. In addition to the high expression of RORγt, CCR6, STAT4, and RUNX4, which are common characteristic transcription factors of Th17, pathogenic Th17 cells also show additional gene signal expression characteristics related to the disease, such as TBX21, IFN-γ, and CXCR3, which have the characteristics of Th1 cell subsets. Pathogenic Th17 cells can secrete high levels of granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-γ, TNF-α, and other cytokines11,12. The phenotype of non-pathogenic Th17 cells is unstable, and only under the stimulation of CD3 and cytokine IL-2 can some of these cells differentiate into pathogenic Th17 cells. Therefore, in common clinical disease models such as rheumatoid arthritis, multiple sclerosis, and acute respiratory distress syndrome, pathogenic Th17 cells primarily exert pathogenic effects.
Pathogenic and non-pathogenic Th17 cells can differentiate in vitro under the influence of different cytokines. In recent years, several studies have proposed methods for inducing the differentiation of Th17 cells using different types and concentrations of cytokines. Th17 cells are stimulated by a combination of IL-6, IL-1β, and IL-2313,14,15,16. It has been proved that IL-6 and TGF-β, two cytokines necessary for Th17 cell differentiation, synergistically regulate the expression of RORγt and Th17 cell differentiation by interacting with two different conserved non-coding DNA sequences at the Rorc gene locus17. The stable phase of pathogenic Th17 cells is mainly maintained by IL-2318,19. IL-23 binds to its receptor and activates the JAK-STAT signaling pathway20, thereby causing phosphorylation of Jak2 and Tyk2 and promoting phosphorylation of STAT1, STAT3, STAT4, and STAT5. IL-4 and IFN-γ are negative regulators of this pathway. However, studies have shown that IL-1β may positively regulate the transcription of Rorα and Rorγt through the mTOR pathway to maintain the stability of the Th17 cell phenotype21.
Due to the heterogeneity of numerous studies, we chose the induction protocols for pathogenic and non-pathogenic Th17 cells from the latest research as controls22. The results indicate that, assuming that everything is carried out according to this protocol, after 5 days of culture under the condition of generating pathogenic Th17, more than 90% of the surviving cells can be pathogenic Th17 cells.
The Institutional Review Committee for Animal Studies at Southeast University approved all the animal studies that are detailed in this study, which were carried out in compliance with both local and institutional office standards. Spleen samples were taken from C57BL6/J mice. Both female and male mice, aged between 5 and 8 weeks, were included in this study. The culture medium and buffer were stored at 4 °C for up to 1 month. Surgical instruments were autoclaved before use. Wear latex gloves and masks to avoid contamination of skin, eyes, and clothing with reagents; use a lot of water or saline rinse for the skin and eyes.
1. Precoating the 24-well tissue culture plate with anti-CD3
2. Mouse spleen isolation and preparation of spleen single-cell suspension
3. Purification of naïve CD4+ T cells based on negative selection of magnetic beads
NOTE: Isolate untouched and highly purified naïve CD4+ T cells (CD4+CD44lowCD62Lhigh) from mouse splenocytes by immunomagnetic negative selection.
4. Induction of pathogenic Th17 cells in vitro
5. Flow cytometric analysis for pathogenic Th17 and Th0 cell differentiation
6. Enzyme-linked immunosorbent assay (ELISA) for detection of IL-17A secretion induced by different media
7. T-cell differentiation by signature gene expression assays via quantitative PCR (qPCR)
NOTE: To rule out the possibility of flow cytometry instability due to the effects of dyes and fixation/rupture, we detected the expression of characteristic genes by qPCR to elucidate the differentiation effect of pathogenic Th17 at the transcriptional level.
Our protocol was developed based on earlier research about pathogenic Th17 cell differentiation. The first step of the experiment is to detect the purity of naïve CD4+ T cells isolated from the spleen by magnetic bead sorting, which is the basis for the success of our subsequent pathogenic Th17 cell differentiation. The purity of naïve CD4+ T cells was detected using surface markers CD62L23 and CD4424 while FOXP325 was used as a marker of Treg cells. We found that the content of Treg cells was significantly reduced after sorting, and the purity of naïve CD4+ T cells could reach at least 95% (Figure 1). To compare the differentiation of pathogenic Th17 cells, naïve CD4+ T cells were cultured with Th0 medium (Table 1) and Th17 differentiation medium (Table 1) for a total of 5 days. It was found that T cells showed cluster growth in both Th0 and Th17 media (Figure 2).
Next, the cells were fixed, permeabilized, and labeled with antibodies against several cytokines in differentiated CD4+ T cells based on flow cytometry. We examined IL17A26 and RORγT27 as the hallmark cytokines of Th17 cell differentiation and found that 90% of naïve CD4+ T cells successfully differentiated into pathogenic Th17 cells under the stimulation of new Th17 cell culture medium (Figure 3). Figure 5 shows the signature genes of Th17 cells detected by PCR, which proved that the pathogenic Th17 cells we obtained by differentiation were stably expressing.
Figure 1: Gating strategy for analysis of signature cytokines in C57BL/6J mouse before and after naïve CD4+ T cell isolation. Abbreviations: FSC-H = forward scatter-peak height; SSC-H = side scatter-peah height; FSC-A = forward scatter-peak area; FITC = fluorescein isothiocyanate; PE = phycoerythrin. Please click here to view a larger version of this figure.
Figure 2: Representative images of mouse naïve CD4+ T cells cultured under pathogenic Th17 and Th0 conditions for 5 days. (A) Th0 cells; (B) pathogenic Th17 cells. Scale bars = 50 µm. Please click here to view a larger version of this figure.
Figure 3: Flow cytometry analysis after differentiation induced by Th0 cell culture medium and Th17 cell culture medium. Abbreviations: FSC-H = forward scatter-peak height; SSC-H = side scatter-peah height; FSC-A = forward scatter-peak area; FITC = fluorescein isothiocyanate; PE = phycoerythrin. Please click here to view a larger version of this figure.
Figure 4: The content of IL-17A in the supernatant of Th0 cell culture medium and Th17 cell culture medium after induction of differentiation. Please click here to view a larger version of this figure.
Figure 5: Representative results of the expression levels of signature cytokines in differentiated CD4+ T cells of C57BL/6J mouse. Please click here to view a larger version of this figure.
Target pathogenic Th17 cell culture medium | Th0 cell culture medium | Classical non-pathogenic Th17 cell culture medium | Classical pathogenic Th17 cell culture medium. | |||||||||||
Reagent | Final concentration | Amount | Final concentration | Amount | Final concentration | Amount | Final concentration | Amount | ||||||
Penicillin-Streptomycin (100x) | 1x | 500 μL | 1x | 500 μL | 1x | 500 μL | 1x | 500 μL | ||||||
Fetal Bovine Serum | 10% | 5 mL | 10% | 5 mL | 10% | 5 mL | 10% | 5 mL | ||||||
β-mercaptoethanol | 50 μM | 50 μL | 50 μM | 50 μL | 50 μM | 50 μL | 50 μM | 50 μL | ||||||
GlutaMAXTM supplement (100x) | 1x | 500 μL | 1x | 500 μL | 1x | 500 μL | 1x | 500 μL | ||||||
Sodium pyruvate solution (100x) | 1 mM | 500 μL | 1 mM | 500 μL | 1 mM | 500 μL | 1 mM | 500 μL | ||||||
Anti-Mouse IFN gamma (1 mg/mL) | 5 µg/mL | 250 μL | 10 µg/mL | 500 μL | 10 µg/mL | 500 μL | ||||||||
Anti-Mouse IL-4 (2 mg/mL) | 5 µg/mL | 125 μL | 5 µg/mL | 250 μL | 10 µg/mL | 250 μL | ||||||||
Mouse rIL-1 beta (20 µg) | 20 ng/mL | NA | ||||||||||||
Mouse rIL-6 (20 µg) | 20 ng/mL | NA | 50 ng/mL | NA | 50 ng/mL | NA | ||||||||
Mouse rIL-23 (50 µg) | 50 ng/mL | NA | 10 ng/mL | NA | ||||||||||
Mouse TGF beta (100 µg) | 3 ng/mL | NA | 1 ng/mL | NA | 1 ng/mL | NA | ||||||||
Murine IL-2 (5 µg) | 20 ng/mL | NA | ||||||||||||
RPMI 1640 | NA | To 50 mL | NA | To 50 mL | NA | To 50 mL | ||||||||
Total | NA | 50 mL | NA | 50 mL | NA | 50 mL |
Table 1: Target pathogenic Th17 cell culture, Th0 cell culture, classical non-pathogenic and pathogenic Th17 cell culture media.
This procedure offered a productive way to increase the number of mice splenic naïve CD4+ T cells for the in vitro production of pathogenic Th17 cells. Although we use more cytokines than other reported Th17 cell culture media, we are committed to optimizing the growth conditions of pathogenic Th17 cells. We are considering further optimization of our induced differentiation protocol.
Here, we simply used flow cytometry and qPCR to examine the production of hallmark cytokines. With a few minor modifications, this approach can also be used for other function tests, such as cell proliferation.
We used a Chinese-produced lymphocyte isolation kit to isolate mouse spleen lymphocytes because it is effective and time-saving. Lymphocyte separation solutions based on other brands can also achieve the purpose of separating mouse spleen lymphocytes through different steps. Another method is to directly lyse the red blood cells of the obtained spleen cell suspension; however, we found that spleen red blood cells often cannot be lysed at one time.
Some problems can arise during the execution of this protocol. First, the number of naïve CD4+ T cells obtained by magnetic bead sorting may be very low (protocol step 3). This could be attributed to the process of crushing organs being insufficient. It is important to ensure that the organ is properly homogenized. Increasing the frequency of rinsing during the homogenization process will improve the recovery rate. To obtain a higher number of splenic naïve CD4+ T cells, we suggest using younger mice (6-10 weeks old). There are various methods available for separating spleen lymphocytes, and the yield may vary depending on the separation liquid used. It is recommended to use a universally certified separation liquid and try to extract the lymphocyte layer as much as possible.
Second, the proportion of CD4+ T cells in flow cytometry may be <80% (protocol step 5). One possible cause of this issue could be an inaccurate splenocyte count, resulting in a cell count greater than that of the additional antibody cocktail and magnetic beads. To increase the effectiveness of naïve CD4+ T cell purification, cell counting must be precise. Additionally, 10% more antibody cocktail and magnetic beads can be used over what this protocol recommends. Lastly, flow cytometry can be performed immediately after sorting naïve CD4+ T cells.
Third, there may not be many T cell clusters formed during the culture, and most of the cells may have died during the differentiation of T cells (protocol step 4). The potential reason for this problem may be the inaccurate determination of cell numbers for naïve CD4+ T cells before seeding, resulting in a low cell density. It is recommended to adopt a more accurate counting method to achieve the desired cell density of approximately 4 × 105 cells/mL for each well in a 48-well plate. Another possible cause could be technical problems with the CO2 incubator, such as incorrect temperature or CO2 concentration. Lastly, excessive force while changing the cell culture medium could potentially cause cell death.
Fourth, the relative expression levels of the signature cytokine genes may be low (protocol step 7). To ensure the authenticity of the extracted RNA, it is recommended to use a nanodroplet detection concentration of more than 100 ng/mL. The potential reason for the decrease in concentration may be the unhealthy nature of cultured cells, such as a large part of the collected cells are dead or in the process of death. To obtain the true RNA concentration, it is necessary to resolve the situation that may lead to poor growth during cell culture. An alternative reason behind this concern might be the excessively low final cell count achieved during RNA extraction, possibly due to inadvertent cell loss during the supernatant disposal. Employing advanced RNA extraction techniques such as one-step RNA extraction kits could prove advantageous. The ideal OD260/OD280 ratio, as measured by Nanodrop, should fall within the range of 1.9-2.1. In the event of an excessively low ratio, protein contamination becomes a possibility. Increasing the frequency of RNase-free buffer washing may aid in mitigating this issue. Conversely, an uncharacteristically low ratio implies potential RNA degradation. To counteract this issue, it is recommended to employ RNase-free water and utilize 1.5 mL tubes for RNase decontamination purposes.
In conclusion, the current protocol describes the use of new cell culture medium to directly induce naive CD4+ T cells to differentiate into pathogenic Th17 cells in vitro. Compared with direct separation, there is no doubt that this method is more direct, inexpensive, and more efficient. The configuration of the medium is also very simple so that the constructed Th17 cells can be more intuitively used for subsequent experiments, providing a very good cell model for the study of many diseases.
The authors have nothing to disclose.
The work was supported by the National Key R&D Program of China (No.2022YFC2304604), National Natural Science Foundation of China (No.81971812), National Natural Science Foundation of China (No.82272235), Science Foundation of the Commission of Health of Jiangsu Province (No. ZDB2020009), Jiangsu Province Key research, development Program (Social Development) Special Project (No.BE2021734), National Key R & D Program of Ministry of Science and Technology (No.2020YFC083700), Jiangsu Provincial Key Laboratory of Critical Care Medicine (BM2020004), Key project of National Natural Science Foundation of China (81930058), National Natural Science Foundation of China (82171717), Central Universities Basic Research Funds (2242022K4007), and Jiangsu Provincial Natural Science Foundation General Project (BK20211170).
Antibodies | |||
Rat anti-mouse CD62L, BV650, clone MEL-14, 1:200 dilution | BD | Cat# 564108; RRID: AB_2738597 | |
Rat monoclonal anti-CD4, FITC, clone RM4-5, 1:200 dilution | BioLegend | Cat#100509; RRID: AB_312712 | |
Rat monoclonal anti-IL-17A, PE, clone TC11-18H10.1, 1:200 dilution | BioLegend | Cat#506903; RRID: AB_ 315463 | |
Rat monoclonal anti mouse/human CD44, APC, clone IM&, 1:200 dilution | BioLegend | Cat#103012; RRID: AB_312963 | |
Rat monoclonal anti-RORγT, APC, clone B2D, 1:200 dilution | Invitrogen | Cat#17-6981-80; RRID: AB_2573253 | |
Rat monoclonal FOXP3 antibody, PE, clone FJK-16s, 1:200 dilution | Invitrogen | Cat#12-5773-82; RRID: AB_465936 | |
Chemicals, peptides, and recombinant proteins | |||
Anti-Mouse CD3 SAFIRE purified | biogems | Cat#05112-25 | |
Anti-Mouse CD28 SAFIRE purified | biogems | Cat#10312-25 | |
Anti-Mouse IFN gamma | biogems | Cat#80822-25 | |
Anti-Mouse IL-4 | biogems | Cat#81112-25 | |
Ethanol | Xilong scientific | Cat#64-17-5 | |
Fetal bovine serum | Gibco | Cat#10437-028 | |
FcR Blocking reagent | Miltenyi Biotec | Cat#130-092-575 | |
GlutaMAX supplement | gibco | Cat#35050079 | |
Mouse rIL-1 beta | Sino Biological | Cat#50101-MNAE | |
Mouse rIL-6 | Sino Biological | Cat#50136-MNAE | |
Mouse rIL-23 | Sino Biological | Cat#CT028-M08H | |
Mouse TGF beta 1 | Sino Biological | Cat#50698-M08H | |
PBS | Procell | Cat#PB180327 | |
Recombinant Murine IL-2 | peprotech | Cat#212-12 | |
RPMI 1640 with L-glutamine | Gibco | Cat#11875-119 | |
Penicillin-streptomycin solution | Gibco | Cat#15070063 | |
β-mercaptoethanol | Sigma-Aldrich | Cat#M6250-100ML | |
Critical commercial assays | |||
Animal Organ Lymphocyte Separation Solution Kit | Tbdscience | Cat#TBD0018SOP | Contains animal spleen tissue lymphocyte separation liquid, tissue sample diluent (cat no. 2010C1119), sample cleaning solution (cat no. 2010X1118), sample washing solution (cat no. TBTDM-W), tissue homogenate flushing liquid (F2013TBD) |
ChamQ SYBR qPCR Master Mix (High ROX Premixed) | Vazyme | Cat#Q341-02 | https://www.vazymebiotech.com/product-center/chamq-sybr-qpcr-master-mix-high-rox-premixed-q341.html. |
Fixation/permeabilization Concentrate | invitrogen | Cat#00-5123-43 | |
Fixation / Permeabilization Diluent | invitrogen | Cat#00-5223-56 | |
Fixable Viability Dye EF506 | invitrogen | Cat#65-0866 | |
HiScript II Q RT SuperMix for qPCR (+gDNA wiper) | Vazyme | Cat#R223-01 | https://www.vazymebiotech.com/product-center/hiscript-ii-q-rt-supermix-for-qpcr-gdna-wiper-r223.html. |
Leukocyte Activation Cocktail | BD | Cat#550583 | |
Mouse IL-17A (Interleukin 17A) ELISA Kit | Elabscience® | Cat#E-EL-M0047 | |
Naïve CD4+ T cells isolation kit, mouse | STEMCELL | Cat#19765 | EasySep kit contains mouse CD4+ T cell isolation cocktail [cat no. 19852C.1], mouse memory T cell depletion cocktail [cat no. 18766C], streptavidin RapidSphered 50001 [cat no. 50001], normal rat serum [cat no. 13551]); only store rat serum at -20 °C; other components to be stored at 2-8 °C. |
Permeabilization Buffer | invitrogen | Cat#00-8333-56 | |
SPARKeasy Cell RNA Kit | Sparkjade | Cat#AC0205-B | https://www.sparkjade.com/product/detail?id=85 |
Experimental models: Organisms/strains | |||
Mouse: C57BL/6 | Gempharmatech | Cat#000013 | |
Oligonucleotides | |||
Mouse Il17a TaqMan primers with probe | ribobio | NA | |
Mouse Il17f TaqMan primers with probe | ribobio | NA | |
Mouse Il23r TaqMan primers with probe | ribobio | NA | |
Mouse Rora TaqMan primers with probe | ribobio | NA | |
β-actin TaqMan primers with probe | ribobio | NA | |
Software and algorithms | |||
Cytek Aurora | Cytek | https://spectrum.cytekbio.com/ | |
FlowJo v10.8.1 | Tree Star | https://www.flowjo.com | |
GraphPad prism 9 | GraphPad Software | https://www.graphpad-prism.cn | |
Other | |||
1 mL syringe | Kindly | NA | |
1.5 mL Centrifuge tubes | Eppendorf | Cat#MCT-150-C | |
5 mL Round-bottom tubes | Corning | Cat#352235 | |
15 mL Centrifuge tubes | NEST | Cat#601052 | |
48-Well tissue culture plate (flatten bottom) | Corning | Cat#3548 | |
50 mL Centrifuge tubes | NEST | Cat#602052 | |
70 µm Cell strainer | Biosharp | Cat#BS-70-XBS | |
96-well Unskirted qPCR Plates | VIOX scientific | Cat#V4801-M | |
100 mm Petri dish | Corning | Cat#430167 | |
Centrifuge | Eppendorf | 5425R | |
Cell culture CO2 incubator | Thermo Fisher | HEPA Class100 | |
Cytek Aurora | Cytek | NA | |
dissecting scissors | RWD | S12003-09 | |
Hemocytometer | AlphaCell | Cat#J633201 | |
NanoDrop 2000 Spectrophotometer | Thermo Fisher | ND-2000 | |
Real-time PCR System | Roche | LightCycler96 | |
Surgical tweezers | RWD | F12005-10 | |
Thermal cycler | Bio-Rad | C1000 Touch |
.